Moderna, Inc. vs Alnylam Pharmaceuticals, Inc.
A head-to-head of Moderna, Inc. (MRNA) and Alnylam Pharmaceuticals, Inc. (ALNY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | MRNA | ALNY |
|---|---|---|
| Market Cap | $19.47B | $41.87B |
| P/E (TTM) | — | 79.94 |
| Forward P/E | -10.81 | 21.24 |
| P/S | 8.44 | 9.77 |
| P/B | 2.61 | 36.31 |
| EV/EBITDA | -6.46 | 44.53 |
| Dividend Yield | — | — |
| Profit Margin | -144.92% | 13.46% |
| Gross Margin | 54.84% | 81.64% |
| Operating Margin | -159.94% | 13.51% |
| Revenue Growth (YoY) | +263.55% | +96.43% |
| FCF Yield | -8.54% | 1.54% |
| Debt / Equity | 7.96 | 93.86 |
| Current Ratio | 2.41 | 3.13 |
Share:
Compare Moderna, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.